MDXG News and Press, MiMedx Group Inc From 01/03/23

MiMedx Group ( NASDAQ: MDXG ) has appointed Ricci S. Whitlow as COO. Most recently she served as President, Clinical Supply Services at Catalent. For further details see: MiMedx appoints Ricci S. Whitlow as Chief Operating Officer

MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership MARIETTA, Ga., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, toda...

Agreement provides MIMEDX with exclusive rights to Turn’s PermaFusion® proprietary antimicrobial intellectual property (IP), accelerating the product development pipeline for wound and surgical recovery applications MARIETTA, Ga., Dec. 08, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, ...

Palm Beach, FL – November 15, 2022 – FinancialNewsMedia.com News Commentary – Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one factor driving expansion in the COPD drug ...

MARIETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the following investor conferences: Ca...

MiMedx Group, Inc. (MDXG) Q3 2022 Earnings Conference Call November 02, 2022 5:00 PM ET Company Participants Matt Notarianni – Head-Investor Relations Todd Newton – Interim Chief Executive Officer Pete Carlson – Chief Financial Officer Ro...

The following slide deck was published by MiMedx Group, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: MiMedx Group, Inc. 2022 Q3 - Results - Earnings Call Presentation

MiMedx Group press release ( NASDAQ: MDXG ): Q3 GAAP EPS of -$0.09 in-line. Revenue of $67.69M (+7.3% Y/Y) beats by $0.96M . The company expects net sales for the fourth quarter 2022 to be in a range of $73M to $76M, which reflects year over year growth in a range ...

Third Quarter Net Sales of $67.7 Million Reflect Growth of 7.3% Introducing Wound & Surgical and Regenerative Medicine Segment Reporting to Highlight Trends Within Each Business Unit Third Quarter Growth Led by Surgical Recovery with Initial Contributions...

MiMedx Group ( NASDAQ: MDXG ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, after market close. The consensus EPS Estimate is -$0.12 (-200.0% Y/Y) and the consensus Revenue Estimate is $66.73M (+5.8% Y/Y). Over the last 3 months, EPS estimate...